We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00229385
First Posted: September 29, 2005
Last Update Posted: December 31, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Prof. Joseph Zohar, Sheba Medical Center
  Purpose
Comparing schizophrenic patients with comorbid OCD and schizophrenic patients without OCD in response to Ziprasidone and in cognitive functioning as compared with OCD patients

Condition Intervention
Schizophrenia Obsessive Compulsive Disorder Drug: Ziprasidone

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

Resource links provided by NLM:


Further study details as provided by Prof. Joseph Zohar, Sheba Medical Center:

Primary Outcome Measures:
  • YBOCS [ Time Frame: 8 weeks ]

Enrollment: 45
Study Start Date: January 2006
Study Completion Date: April 2010
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: Ziprasidone
40-80 mg BID
Active Comparator: 2 Drug: Ziprasidone
40-80 mg BID

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of Schizophrenia and OCD for at least 6 months
  • Minimum score of 14 on YBOCS
  • Minimum score of 60 on PANSS
  • Diagnosis of Schizophrenia without OC symptoms

Exclusion Criteria:

  • Patients who are already being treated with ziprasidone
  • Diagnosis of schizophreniform disorder
  • Organic brain syndrome, mental retardation and pervasive developmental disorder
  • Patients having any significantly cardiovascular illness or electrolyte imbalance
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00229385


Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Tel Aviv University
  More Information

Responsible Party: Prof. Joseph Zohar, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00229385     History of Changes
Other Study ID Numbers: SHEBA-03-3061-JS-CTIL
First Submitted: September 28, 2005
First Posted: September 29, 2005
Last Update Posted: December 31, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Disease
Schizophrenia
Compulsive Personality Disorder
Obsessive-Compulsive Disorder
Pathologic Processes
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Personality Disorders
Anxiety Disorders
Ziprasidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents